Advancing DUB-targeting small molecules
| dc.contributor.advisor | Gersch, Malte | |
| dc.contributor.author | Klink, Nicolas | |
| dc.contributor.referee | Waldmann, Herbert | |
| dc.date.accepted | 2026-10-23 | |
| dc.date.accessioned | 2026-11-17T08:25:29Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Deubiquitinases (DUBs) are key regulators of ubiquitin signaling and have emerged as attractive therapeutic targets. This has driven the development of diverse small-molecule modulators, including catalytic inhibitors, degraders, and recruiter-based modalities. Although early DUB inhibitors often lacked specificity, recent compounds demonstrate that selective and potent targeting of DUBs is achievable. However, key challenges remain, including limited structural understanding of selectivity, incomplete cellular characterization, and insufficient controls for newer modalities such as PROTACs and DUBTACs. This cumulative thesis evaluates and significantly contributed to recent advances in small-molecule DUB modulation, focusing on structural understanding of selectivity and potency, cellular compound benchmarking, quantitative proteome-wide analyses, and genetic or pharmacological control experiments, including two resulting publications that are discussed in more detail. One study examines selective inhibition of USP30, a mitochondrial DUB that negatively regulates PINK1-parkin-mediated mitophagy and is being explored as a therapeutic target in Parkinson’s disease and other mitochondria-linked disorders. A solubility-enhanced derivative of a widely used USP30 inhibitor enabled high-resolution structural analysis, revealing its binding mode and supporting a framework for future structure-based DUB inhibitor design based on shared ligandability hotspots and target-specific compound extensions. A second study focuses on the development and characterization of a USP7 chemical toolbox. USP7 is a multifunctional DUB involved in key cellular pathways such as the p53-MDM2 axis and DNA damage signaling. A matched set of USP7 inhibitors, degraders, and control compounds was designed, synthesized, and evaluated using biochemical, cellular, and proteomics-based assays. Time-resolved studies in pancreatic ductal adenocarcinoma (PDAC) and melanoma cells showed selective regulation of USP7-dependent pathways by degraders, whereas prolonged inhibitor treatment caused broad USP7-independent proteomic and metabolic effects. Together, these studies highlight both the promise and current limitations of DUB-targeting small molecules. Further, they underscore the need for rigorous compound validation, mechanistic controls, and integrated biochemical, structural, cellular, and proteomic characterization to advance DUB modulators as reliable chemical tools for cellular DUB pertubation and therapeutic candidates. | en |
| dc.identifier.uri | http://hdl.handle.net/2003/45271 | |
| dc.identifier.uri | http://dx.doi.org/10.17877/DE290R-27039 | |
| dc.language.iso | en | |
| dc.subject | deubiquitinasen | en |
| dc.subject | PROTACs | en |
| dc.subject | drug discovery | en |
| dc.subject.ddc | 570 | |
| dc.subject.ddc | 540 | |
| dc.subject.rswk | Ubiquitin | en |
| dc.title | Advancing DUB-targeting small molecules | en |
| dc.type | Text | |
| dc.type.publicationtype | PhDThesis | |
| dcterms.accessRights | open access | |
| eldorado.dnb.deposit | true | |
| eldorado.secondarypublication | false |
Dateien
Lizenzbündel
1 - 1 von 1
Lade...
- Name:
- license.txt
- Größe:
- 4.82 KB
- Format:
- Item-specific license agreed upon to submission
- Beschreibung:
